Cited by 629Sinusitis and nasal conditionsAsthma and respiratory diseasesCystic Fibrosis Research Advances

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis

Open access

Gevaert, Philippe, Van Bruaene, Nicholas, Cattaert, Tom, Van Steen, Kristel, Van Zele, Thibaut, Acke, Frederic, De Ruyck, Natalie, Blomme, Katrien, Sousa, Ana R., Marshall, Richard P., Bachert, Claus·2011·Journal of Allergy and Clinical Immunology

DOI 10.1016/j.jaci.2011.07.056

Open this paper in CoChat — free account Open PDF

Abstract

Background Approximately 85% of nasal polyps (NPs) in white subjects are characterized by prominent eosinophilia. IL-5 is the key driver of eosinophilic differentiation and survival. Objective We sought to investigate the therapeutic potential of inhibiting IL-5 with a humanized mAb as treatment for severe nasal polyposis. Methods Thirty patients with severe nasal polyposis (grade 3 or 4 or recurrent after surgery) refractory to corticosteroid therapy were randomized in a double-blind fashion to receive either 2 single intravenous injections (28 days apart) of 750 mg of mepolizumab (n = 20) or placebo (n = 10). Change from baseline in NP score was assessed monthly until 1 month after the last dose (week 8). Computed tomographic scans were also performed at week 8. Results Twelve of 20 patients receiving mepolizumab had a significantly improved NP score and computed tomographic scan score compared with 1 of 10 patients receiving placebo at week 8 versus baseline. Conclusion Mepolizumab achieved a statistically significant reduction in NP size for at least 1 month after dosing in 12 of 20 patients. IL-5 inhibition is a potential novel therapeutic approach in patients with severe eosinophilic nasal polyposis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2011.07.056

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

European Position Paper on Rhinosinusitis and Nasal Polyps 2020
Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., Toppila-Salmi, S., Bernal-Sprekelsen, M., Mullol, J., Alobid, I., et al. (2020) · Rhinology journal · doi:10.4193/rhin20.600 · Cited by 5,882
Self-citation
A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment
Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C. G., & Glimcher, L. H. (2000) · Cell · doi:10.1016/s0092-8674(00)80702-3 · Cited by 3,589
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W. R., Sousa, A. R., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,873
Self-citation
Interleukin-5, eosinophils, and disease
Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.3101 · Cited by 860
Differentiation of chronic sinus diseases by measurement of inflammatory mediators
Zele, T. V., Claeys, S., Gevaert, P., Maele, G. V., Holtappels, G., Cauwenberge, P. V., & Bachert, C. (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01225.x · Cited by 775
Self-citation
A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma
Flood-Page, P. T., Swenson, C. A., Faiferman, I., Matthews, J. G., Williams, M. J. A., Brannick, L., Robinson, D. S., Wenzel, S. E., Busse, W. W., Hansel, T. T., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-085oc · Cited by 750
Total and specific IgE in nasal polyps is related to local eosinophilic inflammation
Bachert, C., Gevaert, P., Holtappels, G., Johansson, S. G. O., & Cauwenberge, P. V. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.112374 · Cited by 702
Self-citation
Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease
Zhang, N., Zele, T. V., Perez-Novo, C. A., Bruaene, N. V., Holtappels, G., Ruyck, N. D., Cauwenberge, P. V., & Bachert, C. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.07.008 · Cited by 621
Self-citation
Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese
Cao, P., Li, H., Wang, B.-F., Wang, S.-B., You, X., Cui, Y., Wang, D. Y., Desrosiers, M. Y., & Liu, Z. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.017 · Cited by 617
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Rothenberg, M. E., Klion, A. D., Roufosse, F. E., Kahn, J., Weller, P. F., Simon, H., Schwartz, L. B., Rosenwasser, L. J., Ring, J., Griffin, E. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa070812 · Cited by 590

Flagged first, then by citations

Show all 31 references

1 of the 31 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 629

Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP
Guo, C., Liu, F., Wang, D. Y., & Liu, Z. (2023) · Current Allergy and Asthma Reports · doi:10.1007/s11882-023-01114-w · Cited by 38
Biomarkers in the evaluation and management of chronic rhinosinusitis with nasal polyposis
Yao, Y., Xie, S., Yang, C., Zhang, J., Wu, X., & Sun, H. (2017) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-017-4547-2 · Cited by 38
Nattokinase, profibrinolytic enzyme, effectively shrinks the nasal polyp tissue and decreases viscosity of mucus
Takabayashi, T., Imoto, Y., Sakashita, M., Kato, Y., Tokunaga, T., Yoshida, K., Narita, N., Ishizuka, T., & Fujieda, S. (2017) · Allergology International · doi:10.1016/j.alit.2017.03.007 · Cited by 38
Bidirectional association between asthma and chronic rhinosinusitis: Two longitudinal follow-up studies using a national sample cohort
Ryu, G., Min, C., Park, B., Choi, H. G., & Mo, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-66479-8 · Cited by 38
Biologic Therapies for Allergic Rhinitis and Nasal Polyposis
Geng, B., Dilley, M., & Anterasian, C. (2021) · Current Allergy and Asthma Reports · doi:10.1007/s11882-021-01013-y · Cited by 40
Behavior of Eosinophil Counts in Recovered and Deceased COVID-19 Patients over the Course of the Disease
Cortés-Vieyra, R., Gutiérrez‐Castellanos, S., Álvarez-Aguilar, C., Baizabal-Aguirre, V. M., Núñez‐Anita, R. E., Rocha-López, A. G., & Gómez‐García, A. (2021) · Viruses · doi:10.3390/v13091675 · Cited by 38
Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up
Desrosiers, M. Y., Diamant, Z., Castelnuovo, P., Hellings, P. W., Han, J. K., Peters, A. T., Silver, J. N., Smith, S. G., Fuller, A., Sousa, A. R., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23219 · Cited by 37
Self-citation
Nasal Polyps
Settipane, R. A., Peters, A. T., & Chiu, A. G. (2013) · American Journal of Rhinology and Allergy · doi:10.2500/ajra.2013.27.3926 · Cited by 37
Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?
Tsilochristou, O., Douladiris, N., Makris, M. P., & Papadopoulos, N. G. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0043-3 · Cited by 36
Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review
de Rooij, W. E., Dellon, E. S., Parker, C. E., Feagan, B. G., Jairath, V., Ma, C., & Bredenoord, A. J. (2019) · Drugs · doi:10.1007/s40265-019-01173-2 · Cited by 37
Activation-Induced Cytidine Deaminase (AID)-Associated Multigene Signature to Assess Impact of AID in Etiology of Diseases with Inflammatory Component
Mechtcheriakova, D., Sobanov, Y., Holtappels, G., Bajna, E., Svoboda, M., Jaritz, M., Bachert, C., & Jensen‐Jarolim, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025611 · Cited by 37
Self-citation
Clinical characteristics and cytokine profiles of central‐compartment‐type chronic rhinosinusitis
Lin, Y., Lin, C., Liao, S. C., Chiang, B., & Yeh, T. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22759 · Cited by 36
Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression
Schleimer, R. P., Schnaar, R. L., & Bochner, B. S. (2015) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000234 · Cited by 36
Strategies to reduce corticosteroid-related adverse events in asthma
Heffler, E. M., Bagnasco, D., & Canonica, G. W. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000493 · Cited by 36
Therapeutic Antibodies for Nasal Polyposis Treatment: Where Are We Headed?
Agarwal, A., Spath, D., Sherris, D. A., Kita, H., & Ponikau, J. U. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08734-z · Cited by 36
Novel findings in immunopathophysiology of chronic rhinosinusitis and their role in a model of precision medicine
Xu, X., Ong, Y. K., & Wang, D. Y. (2019) · Allergy · doi:10.1111/all.14044 · Cited by 35
Aspirin-exacerbated respiratory disease: not always “adult-onset”
Tuttle, K. L., Schneider, T. R., Henrickson, S. E., Morris, D., Abonia, J. P., Spergel, J. M., & Laidlaw, T. M. (2016) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2016.05.016 · Cited by 36
Eosinophils—from cradle to grave
Jeseňák, M., Diamant, Z., Simon, D., Tufvesson, E., Seys, S., Mukherjee, M., Lacy, P., Vijverberg, S. J. H., Slisz, T., Šedivá, A., et al. (2023) · Allergy · doi:10.1111/all.15884 · Cited by 38
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
Lombardi, C., Comberiati, P., Ridolo, E., Cottini, M., Yacoub, M., Casagrande, S., Riccò, M., Bottazzoli, M., & Berti, A. (2024) · Drugs · doi:10.1007/s40265-024-02037-0 · Cited by 35
Aspirin Sensitivity and Chronic Rhinosinusitis with Polyps: A Fatal Combination
Graefe, H., Roebke, C., Schäfer, D., & Meyer, J. E. (2012) · Journal of Allergy · doi:10.1155/2012/817910 · Cited by 35
Is there a future for biologics in the management of chronic rhinosinusitis?
Lam, K. K., Kern, R. C., & Luong, A. (2016) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21780 · Cited by 35
Biological Therapy of Severe Asthma and Nasal Polyps
Bakakos, A., Schleich, F., & Bakakos, P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060976 · Cited by 35
Structural organization and cellular localization of tuftelin-interacting protein 11 (TFIP11)
Wen, X., Lei, Y., Zhou, Y. L., Okamoto, C. T., Snead, M. L., & Paine, M. L. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4547-z · Cited by 35
Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps
Kratchmarov, R., Dharia, T., & Buchheit, K. M. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.03.011 · Cited by 34
Role of Innate Immunity in the Pathogenesis of Chronic Rhinosinusitis: Progress and New Avenues
van Drunen, C. M., Mjösberg, J., Segboer, C. L., Cornet, M., & Fokkens, W. J. (2012) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0249-4 · Cited by 34
Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances
Steinke, J. W., & Wilson, J. M. (2016) · Journal of Asthma and Allergy · doi:10.2147/jaa.s88739 · Cited by 34
Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps
Xian, M., Yan, B., Song, X., Chen, J., Tang, J., Jiang, Y., Wan, L., Liu, W., Xue, J., Cao, Z., et al. (2025) · Allergy · doi:10.1111/all.16519 · Cited by 33
Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review
Kim, C. M., Han, J. K., Wu, T. J., Bachert, C., Fokkens, W. J., Hellings, P. W., Hopkins, C. L., Lee, S., Mullol, J., & Lee, J. T. (2020) · Otolaryngology · doi:10.1177/0194599820939964 · Cited by 33
Self-citation
Treatment options for chronic rhinosinusitis with nasal polyps
Wallace, D. V. (2021) · Allergy and Asthma Proceedings · doi:10.2500/aap.2021.42.210080 · Cited by 33
Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: Review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8
Na, H. J., Hamilton, R. G., Klion, A. D., & Bochner, B. S. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.05.017 · Cited by 33
Aeroallergens, air pollutants, and chronic rhinitis and rhinosinusitis
London, N. R., Lina, I. A., & Ramanathan, M. (2018) · World Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.1016/j.wjorl.2018.08.006 · Cited by 32
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments
Lombardi, C., Asero, R., Bagnasco, D., Blasi, F., Bonini, M., Bussi, M., Canevari, F. R., Canonica, G. W., Castelnuovo, P., Cecchi, L., et al. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100592 · Cited by 32
The Diagnostic and Prognostic Role of Biomarkers in Chronic Rhinosinusitis
Seah, J. J., Thong, M. K. T., & Wang, D. Y. (2023) · Diagnostics · doi:10.3390/diagnostics13040715 · Cited by 31
A prospective analysis evaluating tissue biopsy location and its clinical relevance in chronic rhinosinusitis with nasal polyps
Weibman, A. R., Huang, J. H., Stevens, W. W., Suh, L. A., Price, C. P. E., Lidder, A. K., Conley, D. B., Welch, K. C., Smith, S. S., Peters, A. T., et al. (2017) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22005 · Cited by 31
A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps
Codispoti, C. D., & Mahdavinia, M. (2019) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2019.07.004 · Cited by 31
Barrier Impairment and Type 2 Inflammation in Allergic Diseases: The Pediatric Perspective
Ghezzi, M., Pozzi, E., Abbattista, L., Lonoce, L., Zuccotti, G., & D’Auria, E. (2021) · Children · doi:10.3390/children8121165 · Cited by 35
Surgical Versus Medical Interventions in CRS and Nasal Polyps: Comparative Evidence Between Medical and Surgical Efficacy
Dessouky, O., & Hopkins, C. L. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0566-5 · Cited by 32
Is there a role for antibiotics in the treatment of chronic rhinosinusitis?
Smith, S. S., Kim, R., & Douglas, R. G. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.02.004 · Cited by 33
Programmed cell death‐1 expression correlates with disease severity and IL‐5 in chronic rhinosinusitis with nasal polyps
Krohn, I. K., Bobic, S., Dooley, J., Lan, F., Zhang, N., Bachert, C., Steelant, B., Bullens, D. M. A., Liston, A., Ceuppens, J. L., et al. (2017) · Allergy · doi:10.1111/all.13136 · Cited by 30
Self-citation
Systematic Review of Long Term Sinonasal Outcomes in CRSwNP after Endoscopic Sinus Surgery: A call for Unified and Standardized Criteria and Terms
Rodríguez, C., Arancibia, C., Calvo‐Henríquez, C., Mullol, J., & Alobid, I. (2024) · Current Allergy and Asthma Reports · doi:10.1007/s11882-024-01154-w · Cited by 29
Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis
Stevens, W. W., Buchheit, K. M., & Cahill, K. N. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0569-2 · Cited by 29
Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study
Yılmaz, İ., Türk, M., Bahçecioğlu, S. N., Tutar, N., & Gülmez, İ. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1912-62 · Cited by 29
Which Factors Associated With Activated Eosinophils Contribute to the Pathogenesis of Aspirin-Exacerbated Respiratory Disease?
Choi, Y., Lee, Y., & Park, H. (2019) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2019.11.3.320 · Cited by 29
Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyposis
Boyle, J. V., Lam, K. K., & Han, J. K. (2020) · Immunotherapy · doi:10.2217/imt-2019-0191 · Cited by 30
Chronic Rhinosinusitis—Microbiological Etiology, Potential Genetic Markers, and Diagnosis
Michalik, M., & Krawczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063201 · Cited by 33
Type 2 immunity‐driven diseases: Towards a multidisciplinary approach
Hassoun, D., Malard, O., Barbarot, S., Magnan, A., & Colas, L. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.14029 · Cited by 31
Remodeling and Repair in Rhinosinusitis
Watelet, J., Dogné, J., & Mullier, F. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0531-3 · Cited by 28
Uses of biologics in allergic diseases
Saco, T. V., Pepper, A. N., & Casale, T. B. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.02.029 · Cited by 28
Targeting eosinophils: severe asthma and beyond
Caminati, M., Menzella, F., Guidolin, L., & Senna, G. (2019) · Drugs in Context · doi:10.7573/dic.212587 · Cited by 27
Targeted Molecular Therapies in Allergy and Rhinology
Damask, C. C., Ryan, M. W., Casale, T. B., Castro, M., Franzese, C. B., Lee, S. E., Levy, J. M., Lin, S. Y., Lio, P., Peters, A. T., et al. (2020) · Otolaryngology · doi:10.1177/0194599820965233 · Cited by 27
The Role of Biologics in Chronic Rhinosinusitis with Nasal Polyps
Bachert, C., Desrosiers, M. Y., Hellings, P. W., & Laidlaw, T. M. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.11.017 · Cited by 27
Self-citation
Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis
Fokkens, W. J., van der Lans, R. J. L., & Reitsma, S. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1901881 · Cited by 28
Insights into the Implications of Coexisting Type 2 Inflammatory Diseases
McCormick, J. P., & Lee, J. T. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s311640 · Cited by 27
Low-dose mepolizumab is effective as an add-on therapy for treating long-lasting peripheral neuropathy in patients with eosinophilic granulomatosis with polyangiitis
Nakamura, Y., Fukutomi, Y., Sekiya, K., 梶原, 景., Kawasaki, Y., Fujita, N., Nagayama, K., Iwata, M., Iwamoto, K., Yano, K., et al. (2021) · Modern Rheumatology · doi:10.1093/mr/roab005 · Cited by 27
Novel Therapies for Eosinophilic Disorders
Bochner, B. S. (2015) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.05.007 · Cited by 27
Choice of biologics in asthma endotypes
Wangberg, H., & Woessner, K. M. (2020) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000708 · Cited by 26
Wogonin attenuates nasal polyp formation by inducing eosinophil apoptosis through HIF-1α and survivin suppression
Khalmuratova, R., Lee, M., Mo, J., Jung, Y., Park, J., & Shin, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-24356-5 · Cited by 26
An update on the role of chronic rhinosinusitis with nasal polyps as a co-morbidity in severe asthma
Castagnoli, R., Licari, A., Brambilla, I., Tosca, M., Ciprandi, G., & Marseglia, G. L. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1812388 · Cited by 29
Local immunoglobulin production in nasal tissues
Buchheit, K. M., & Hulse, K. E. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.09.016 · Cited by 26
The optimal evaluation and management of patients with a gradual onset of olfactory loss
Enríquez, K., Lehrer, E., & Mullol, J. (2013) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000013 · Cited by 25
Therapeutic Strategies for Harnessing Human Eosinophils in Allergic Inflammation, Hypereosinophilic Disorders, and Cancer
Amini, Z., Martinez-Moczygemba, M., & Huston, D. P. (2012) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0290-3 · Cited by 25
Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab
Oda, N., Miyahara, N., Senoo, S., Itano, J., Taniguchi, A., Morichika, D., Fujii, U., Maeda, Y., Kiura, K., & Kanehiro, A. (2018) · Allergology International · doi:10.1016/j.alit.2018.03.004 · Cited by 25
Severe refractory asthma: current treatment options and ongoing research
Menzella, F., Bertolini, F., Biava, M., Galeone, C., Scelfo, C., & Caminati, M. (2018) · Drugs in Context · doi:10.7573/dic.212561 · Cited by 24
Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease
Howe, R., Mirakian, R. M., Pillai, P., Gane, S. B., Darby, Y., & Scadding, G. K. (2014) · World Allergy Organization Journal · doi:10.1186/1939-4551-7-18 · Cited by 25
Real-Life Evidence of Mepolizumab Treatment in Chronic Rhinosinusitis with Nasal Polyps: A Multicentric Study
Cavaliere, C., Loperfido, A., Ciofalo, A., Michele, L. D., Begvarfaj, E., Bellocchi, G., Bugani, M., VINCENTIIS, M. D., Greco, A., Millarelli, S., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123575 · Cited by 24
Current understanding of allergic fungal rhinosinusitis and treatment implications
Plonk, D. P., & Luong, A. (2014) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000043 · Cited by 24
Aspirin or Nonsteroidal Anti-inflammatory Drug–Exacerbated Chronic Rhinosinusitis
Ledford, D. K., & Lockey, R. F. (2016) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2016.04.011 · Cited by 24
Chronic Rhinosinusitis Phenotypes: An Approach to Better Medical Care for Chronic Rhinosinusitis
Cho, S., Bachert, C., & Lockey, R. F. (2016) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2016.05.007 · Cited by 24
Self-citation
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations
Bagnasco, D., Ferrando, M., Caminati, M., Bragantini, A., Puggioni, F., Varricchi, G., Passalacqua, G., & Canonica, G. W. (2017) · Drug Safety · doi:10.1007/s40264-017-0522-5 · Cited by 24
Endotypes of chronic rhinosinusitis
Yip, J., Monteiro, E., & Chan, Y. (2018) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000503 · Cited by 24
Aspirin-exacerbated respiratory disease
Pham, D. L., Lee, J.-H., & Park, H. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000328 · Cited by 23
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
Haldar, P. (2017) · Biologics · doi:10.2147/btt.s93954 · Cited by 23
Local free light chain expression is increased in chronic rhinosinusitis with nasal polyps
Kormelink, T. G., Calus, L., Ruyck, N. D., Holtappels, G., Bachert, C., Redegeld, F. A., & Gevaert, P. (2012) · Allergy · doi:10.1111/j.1398-9995.2012.02866.x · Cited by 22
Self-citation
Anti-interleukin (IL)-5 as a steroid-sparing agent in chronic eosinophilic pneumonia
Sarkis, E., Patel, S. K., Burns, K., Batarseh, H., & Mador, M. J. (2018) · Journal of Asthma · doi:10.1080/02770903.2018.1543434 · Cited by 23
NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets
Laidlaw, T. M., & Levy, J. M. (2020) · Current Allergy and Asthma Reports · doi:10.1007/s11882-020-00905-9 · Cited by 23
Systemic medication requirement in post-surgical patients with eosinophilic chronic rhinosinusitis
Ho, J., Li, W., Grayson, J. W., Alvarado, R., Rimmer, J., Sewell, W. A., & Harvey, R. J. (2020) · Rhinology Journal · doi:10.4193/rhin20.073 · Cited by 23
Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential
Menzella, F., Lusuardi, M., Galeone, C., Taddei, S., Facciolongo, N. C., & Zucchi, L. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622316659863 · Cited by 22
Tissue and Exosomal Serine Protease Inhibitors Are Significantly Overexpressed in Chronic Rhinosinusitis With Nasal Polyps
Mueller, S. K., Nocera, A. L., Dillon, S. T., Libermann, T. A., Wendler, O., & Bleier, B. S. (2019) · American Journal of Rhinology and Allergy · doi:10.1177/1945892419831108 · Cited by 22
Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis
Tsurumaki, H., Matsuyama, T., Ezawa, K., Koga, Y., Yatomi, M., Aoki‐Saito, H., Chikamatsu, K., & Hisada, T. (2019) · Medicina · doi:10.3390/medicina55070336 · Cited by 22
Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease
Eid, R. C., Yan, C. H., Stevens, W. W., Doherty, T. A., & Borish, L. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.06.016 · Cited by 22
Evaluating metrics of responsiveness using patient‐reported outcome measures in chronic rhinosinusitis
Lidder, A. K., Detwiller, K. Y., Price, C. P. E., Kern, R. C., Conley, D. B., Smith, S. S., Welch, K. C., Chandra, R. K., Peters, A. T., Grammer, L. C., et al. (2016) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21866 · Cited by 22
Medical therapy, refractory chronic rhinosinusitis, and productivity costs
Smith, K. A., & Rudmik, L. R. (2016) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000329 · Cited by 22
The Role of Biologics in the Treatment of Nasal Polyps
Franzese, C. B. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2019.12.006 · Cited by 22
Exploring causal relationships between inflammatory cytokines and allergic rhinitis, chronic rhinosinusitis, and nasal polyps: a Mendelian randomization study
Li, L., Zhang, Y., Liu, H., Wang, T., Li, J., & Wang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1288517 · Cited by 23
Adverse events for biologics in patients with CRSwNP: A meta‐analysis
Shen, Y., Ke, X., Hong, S., & Yang, Y. (2022) · Clinical and Translational Allergy · doi:10.1002/clt2.12169 · Cited by 21
Therapie der chronischen Rhinosinusitis mit Polyposis nasi (CRScNP) mit monoklonalen Antikörpern (Biologika): S2k-Leitlinie der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC) und der Deutschen Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM)
Pfaar, O., Beule, A. G., Laudien, M., Stuck, B. A., CRScNP‘, E. L. ‚. B., Aletsee, C., Klimek, L., Milger, K., Popert, U., Rose, M., et al. (2023) · HNO · doi:10.1007/s00106-023-01273-2 · Cited by 21
Evolution in the surgical management of chronic rhinosinusitis: Current indications and pitfalls
Kohanski, M. A., Toskala, E. M., & Kennedy, D. W. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.03.003 · Cited by 21
New biologics for allergic diseases
Manka, L. A., & Wechsler, M. E. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1459188 · Cited by 21
Immunologie der Polyposis nasi als Grundlage für eine Therapie mit Biologicals
Klimek, L., Koennecke, M., Hagemann, J., Wollenberg, B., & Becker, S. (2018) · HNO · doi:10.1007/s00106-018-0557-7 · Cited by 21
Chronic rhinosinusitis with nasal polyps: insights into mechanisms of disease from emerging biological therapies
Kariyawasam, H. H. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1541738 · Cited by 21
Regulation of Human Innate Lymphoid Cells in the Context of Mucosal Inflammation
Schulz-Kuhnt, A., Wirtz, S. J., Neurath, M. F., & Atreya, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01062 · Cited by 21
Mepolizumab decreases tissue eosinophils while increasing type‐2 cytokines in eosinophilic chronic rhinosinusitis
Walter, S., Ho, J., Alvarado, R., Smith, G. W., Croucher, D. R., Liang, S., Grayson, J. W., Mangussi‐Gomes, J., Es, S. L. V., Earls, P., et al. (2022) · Clinical & Experimental Allergy · doi:10.1111/cea.14152 · Cited by 21
The advance on pathophysiological mechanisms of type 2 chronic rhinosinusitis with nasal polyposis
Yang, C., Guo, L., Wang, Y., Jiang, W., Chen, S., & Gu, Q. (2025) · Frontiers in Allergy · doi:10.3389/falgy.2025.1599797 · Cited by 24
Activation of group 2 innate lymphoid cells exacerbates and confers corticosteroid resistance to mouse nasal type 2 inflammation
Morikawa, T., Fukuoka, A., Matsushita, K., Yasuda, K., Iwasaki, N., Akasaki, S., Fujieda, S., & Yoshimoto, T. (2017) · International Immunology · doi:10.1093/intimm/dxx030 · Cited by 20
Novel therapeutic targets for allergic airway disease in children
Giallongo, A., Parisi, G. F., Licari, A., Pulvirenti, G., Cuppari, C., Salpietro, C. D., Marseglia, G. L., & Leonardi, S. (2019) · Drugs in Context · doi:10.7573/dic.212590 · Cited by 20
Granulocyte-colony stimulating factor: Missing link for stratification of type 2–high and type 2–low chronic rhinosinusitis patients
Nevel, S. V., Declercq, J., Holtappels, G., Lambrecht, B. N., & Bachert, C. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.02.019 · Cited by 20
Self-citation
Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: A systematic review
Aldajani, A., Alroqi, A. S., Alromaih, S., Aloulah, M., & Alsaleh, S. A. (2022) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2022.103615 · Cited by 22
Canadian multidisciplinary expert consensus on the use of biologics in upper airways: A Delphi study
Thamboo, A. V., Lee, M., Bhutani, M., Chan, C. K., Chan, Y., Chapman, K. R., Chin, C. J., Connors, L. A., Dorscheid, D., Ellis, A. K., et al. (2023) · Journal of Otolaryngology - Head and Neck Surgery · doi:10.1186/s40463-023-00626-9 · Cited by 20
Lack of Efficacy of Symptoms and Medical History in Distinguishing the Degree of Eosinophilia in Nasal Polyps
Steinke, J. W., Smith, A. R., Carpenter, D. J., Patrie, J. T., Payne, S. C., & Borish, L. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.04.009 · Cited by 20
Understanding and clinical relevance of chronic rhinosinusitis endotypes
Husain, Q. M., & Sedaghat, A. R. (2019) · Clinical Otolaryngology · doi:10.1111/coa.13455 · Cited by 20

Authors: Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., Blomme, K., Sousa, A. R., Marshall, R. P., & Bachert, C.
Affiliations: Ghent University (BE)
University of Liège (BE)
GlaxoSmithKline (United Kingdom) (GB)
Corresponding author: Gevaert, Philippe
ORCID: Gevaert, Philippe
Acke, Frederic
Sousa, Ana R.
Marshall, Richard P.
Bachert, Claus
Venue: Journal of Allergy and Clinical Immunology
Publisher: Elsevier BV
Published: 2011-11
Volume: 128
Issue: 5
Pages: 989-995.e8
ISSN: 0091-6749 (ISSN-L)
DOI: 10.1016/j.jaci.2011.07.056
OpenAlex: W1968876836
Cited by: 629
References: 31
Citations by year: 2026: 21 · 2025: 26 · 2024: 31 · 2023: 45 · 2022: 29 · 2021: 73 · 2020: 80 · 2019: 56 · 2018: 64 · 2017: 55 · 2016: 52 · 2015: 36 · 2014: 15 · 2013: 16 · 2012: 27
FWCI: 17.13
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Allergy and Clinical Immunology (publishedVersion)
PubMed (publishedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Lirias (submittedVersion)
ORBi (University of Liège) (submittedVersion)
Funders: GlaxoSmithKline
Fonds De La Recherche Scientifique - FNRS
Fonds Wetenschappelijk Onderzoek
Vlaamse regering
Topics: Health Sciences › Medicine › Otorhinolaryngology › Sinusitis and nasal conditions
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Keywords: mepolizumab, IL-5 inhibition, nasal polyps, eosinophilic rhinosinusitis, humanized monoclonal antibody, corticosteroid-refractory disease, eosinophilia, anti-IL-5 therapy
MeSH terms: Double-Blind Method, Eosinophilia, Female, Humans, Male, Middle Aged, Nasal Polyps, Interleukin-5, Eosinophil Cationic Protein, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks